 |
In the CARE
trial, there appeared to be no relation between the change in CRP and the change in LDL-C
attained by use of the study drug. Among patients with a similar reduction in LDL-C, those
who had an LDL-C reduction on placebo had an increase in CRP, whereas those who had the
same LDL-C reduction on pravastatin had a decrease in CRP. These data have also now been
confirmed with several other statins and emphasize that statin therapy may involve several
mechanisms in addition to reduction of LDL-C. Reference:
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent
Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of
C-reactive protein. Circulation 1999;100:230-235.
Web
site |
